KR101355118B1 - Ｎｏｇｏ에 유도되는 면역글로불린 - Google Patents

Ｎｏｇｏ에 유도되는 면역글로불린 Download PDF

Info

Publication number
KR101355118B1
KR101355118B1 KR1020087017348A KR20087017348A KR101355118B1 KR 101355118 B1 KR101355118 B1 KR 101355118B1 KR 1020087017348 A KR1020087017348 A KR 1020087017348A KR 20087017348 A KR20087017348 A KR 20087017348A KR 101355118 B1 KR101355118 B1 KR 101355118B1
Authority
KR
South Korea
Prior art keywords
ser
leu
val
lys
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087017348A
Other languages
English (en)
Korean (ko)
Other versions
KR20080080644A (ko
Inventor
스테파니 제인 크레그
조나단 헨리 엘리스
볼커 게르마쉬브스키
폴 앤드류 험블린
조지 콥시다스
루쓰 맥아담
라빈더 쿠마 프린자
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35736284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101355118(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Publication of KR20080080644A publication Critical patent/KR20080080644A/ko
Application granted granted Critical
Publication of KR101355118B1 publication Critical patent/KR101355118B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020087017348A 2005-12-16 2006-12-14 Ｎｏｇｏ에 유도되는 면역글로불린 Expired - Fee Related KR101355118B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0525662.3A GB0525662D0 (en) 2005-12-16 2005-12-16 Immunoglobulins
GB0525662.3 2005-12-16
PCT/EP2006/069737 WO2007068750A2 (en) 2005-12-16 2006-12-14 Immunoglobulins directed against nogo

Publications (2)

Publication Number Publication Date
KR20080080644A KR20080080644A (ko) 2008-09-04
KR101355118B1 true KR101355118B1 (ko) 2014-02-06

Family

ID=35736284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087017348A Expired - Fee Related KR101355118B1 (ko) 2005-12-16 2006-12-14 Ｎｏｇｏ에 유도되는 면역글로불린

Country Status (30)

Country Link
US (2) US8362208B2 (enExample)
EP (2) EP1960429B1 (enExample)
JP (1) JP5015949B2 (enExample)
KR (1) KR101355118B1 (enExample)
CN (1) CN101374863B (enExample)
AR (1) AR057239A1 (enExample)
AU (1) AU2006325228B2 (enExample)
BR (1) BRPI0619855A2 (enExample)
CA (1) CA2633501C (enExample)
CR (1) CR10099A (enExample)
CY (1) CY1113094T1 (enExample)
DK (1) DK1960429T3 (enExample)
EA (1) EA015536B1 (enExample)
ES (1) ES2389380T3 (enExample)
GB (1) GB0525662D0 (enExample)
HR (1) HRP20120684T1 (enExample)
IL (1) IL192086A0 (enExample)
JO (1) JO2795B1 (enExample)
MA (1) MA30041B1 (enExample)
MY (1) MY149492A (enExample)
NO (1) NO20082699L (enExample)
NZ (1) NZ569143A (enExample)
PE (1) PE20071099A1 (enExample)
PL (1) PL1960429T3 (enExample)
PT (1) PT1960429E (enExample)
SI (1) SI1960429T1 (enExample)
TW (1) TWI378940B (enExample)
UA (1) UA96279C2 (enExample)
WO (1) WO2007068750A2 (enExample)
ZA (2) ZA200805111B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
JP5698534B2 (ja) * 2007-11-02 2015-04-08 ノバルティス アーゲー 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
PE20091965A1 (es) 2008-05-06 2010-01-09 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
WO2010004031A2 (en) * 2008-07-11 2010-01-14 Glaxo Group Limited Novel treatment
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
WO2014006105A1 (en) 2012-07-05 2014-01-09 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
US11013815B2 (en) 2017-06-14 2021-05-25 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
JP7617040B2 (ja) * 2019-06-13 2025-01-17 プレステージ バイオファーマ リミテッド Ｃｔｈｒｃ１に特異的な新規抗体及びその使用
PH12022550992A1 (en) 2019-10-24 2023-09-25 Novago Therapeutics Ag Novel anti-nogo-a antibodies
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
MX2023015152A (es) 2021-06-17 2024-05-31 Petmedix Ltd Anticuerpos anti-cd20 canino.
AU2022369106B2 (en) 2021-10-21 2025-10-02 Zoetis Services Uk Limited Proteins comprising the extracellular domain of p75ntr
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
JP2025506488A (ja) 2022-02-09 2025-03-11 ペットメディックス・リミテッド 治療抗体
CN119768424A (zh) * 2022-08-22 2025-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
GB202217993D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Therapeutic antibodies
EP4662226A1 (en) 2023-02-09 2025-12-17 Zoetis Services UK Limited Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061544A2 (en) * 2003-12-22 2005-07-07 Glaxo Group Limited Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
SK282722B6 (sk) 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. N-(alfa-Etylbenzyl)-3-hydroxy-2-fenylchinolín-4-karboxamid, farmaceutický prípravok s jeho obsahom a jeho použitie
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
ATE275415T1 (de) 1995-06-27 2004-09-15 Res Foundation Of Cuny Hunter Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
WO2000005364A1 (en) 1998-07-22 2000-02-03 Smithkline Beecham Plc Protein similar to neuroendrocrine-specific protein, and encoding cdna
ES2529196T3 (es) 1998-11-06 2015-02-17 University Of Zurich Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas
FR2792199B3 (fr) 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
DE10338136A1 (de) 2003-08-15 2005-03-24 European Molecular Biology Laboratory Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
JP4782700B2 (ja) * 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
WO2005097184A2 (en) * 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061544A2 (en) * 2003-12-22 2005-07-07 Glaxo Group Limited Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Also Published As

Publication number Publication date
BRPI0619855A2 (pt) 2011-10-25
SI1960429T1 (sl) 2012-09-28
US20100221260A1 (en) 2010-09-02
CY1113094T1 (el) 2016-04-13
ZA200805111B (en) 2009-12-30
DK1960429T3 (da) 2012-09-24
HRP20120684T1 (hr) 2012-09-30
KR20080080644A (ko) 2008-09-04
HK1119720A1 (en) 2009-03-13
NO20082699L (no) 2008-09-08
MA30041B1 (fr) 2008-12-01
CN101374863B (zh) 2013-05-29
NZ569143A (en) 2011-08-26
TWI378940B (en) 2012-12-11
PL1960429T3 (pl) 2012-11-30
AR057239A1 (es) 2007-11-21
EP1960429B1 (en) 2012-06-27
JP5015949B2 (ja) 2012-09-05
US20130287781A1 (en) 2013-10-31
PT1960429E (pt) 2012-09-25
US8362208B2 (en) 2013-01-29
ZA200906162B (en) 2010-05-26
EA015536B1 (ru) 2011-08-30
EA200801343A1 (ru) 2008-12-30
PE20071099A1 (es) 2007-11-22
UA96279C2 (ru) 2011-10-25
JO2795B1 (en) 2014-03-15
IL192086A0 (en) 2008-12-29
CR10099A (es) 2008-09-22
MY149492A (en) 2013-09-13
CA2633501C (en) 2015-03-31
TW200801038A (en) 2008-01-01
CA2633501A1 (en) 2007-06-21
AU2006325228B2 (en) 2011-12-15
EP1960429A2 (en) 2008-08-27
CN101374863A (zh) 2009-02-25
EP2228391A2 (en) 2010-09-15
JP2009519025A (ja) 2009-05-14
GB0525662D0 (en) 2006-01-25
WO2007068750A2 (en) 2007-06-21
EP2228391A3 (en) 2010-12-29
WO2007068750A3 (en) 2007-11-29
ES2389380T3 (es) 2012-10-25
AU2006325228A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
KR101355118B1 (ko) Ｎｏｇｏ에 유도되는 면역글로불린
JP5919188B2 (ja) Ｉｌ−１３結合タンパク質
JP6236478B2 (ja) 血清アミロイドｐ成分に特異的な抗原結合タンパク質
BRPI0808087A2 (pt) anticorpo ou fragmento de ligante de antÍgeno do mesmo, cÉlula hospedeira recombinante transformada, transfectada ou transduzida, mÉtodo para a produÇço de anticorpo ou de fragmento de ligante de antÍgeno do mesmo, composiÇço farmacÊutica, kit-de-partes, mÉtodo para tratar paciente humano afligido com cÂncer, e, uso de anticorpo ou fragmento de ligante de antÍgeno do mesmo
JP6351973B2 (ja) 抗原結合タンパク質
IL188282A (en) Monoclonal antibody that binds and neutralizes human nogo, a pharmaceutical composition comprising it and uses thereof
CN101258165B (zh) Nogo-a对人抗体有特效和它的药学应用
TW202417509A (zh) Slit2相關組合物和方法
HK1142344A (en) Immunoglobulins directed against nogo
HK1119720B (en) Immunoglobulins directed against nogo
HK1115598B (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170118

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170118

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000